Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2017-02-28 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Director's Dealing 2017
Director's Dealing Classification · 99% confidence The document text is structured as a formal report detailing transactions executed by individuals holding management responsibility ('personer med ledelsesansvar') and their closely associated persons. Key fields include 'Stilling/titel' (Position/Title), 'Transaktionens art' (Type of transaction), 'Pris(er) og mængde(r)' (Price(s) and Quantity(ies)), and 'Dato for transaktionen' (Date of transaction). This format is characteristic of mandatory regulatory filings disclosing insider trading or director dealings, specifically concerning transactions by directors and executives. Based on the provided definitions, this aligns perfectly with 'Director's Dealing' (Code: DIRS).
2017-02-28 Danish
Director's Dealing 2017
Director's Dealing Classification · 99% confidence The document text is explicitly titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details transactions (subscription of shares/exercise of warrants) conducted by senior management (CEO, CFO, Board member) of the issuer (Genmab A/S). This type of mandatory disclosure concerning insider trading or executive share transactions directly corresponds to the definition of Director's Dealing (DIRS).
2017-02-28 English
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement detailing a specific increase in share capital resulting from the exercise of employee warrants. It provides a breakdown of the shares issued at various prices and the resulting total nominal value of the company's share capital. This falls directly under the definition of a 'Share Issue/Capital Change' (SHA) announcement.
2017-02-28 English
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 96% confidence The document is a company announcement detailing a capital increase through the issuance of 385,087 new shares due to exercise of employee warrants, specifying share subscription prices, total proceeds, share rights, and listing details. This clearly fits the definition of a share issue/capital change announcement rather than a full financial report or other type. Therefore, the correct classification is SHA (Share Issue/Capital Change).
2017-02-28 English
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement from Genmab A/S regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on the total share capital, and the total number of voting rights. This falls under the category of share issuance and capital changes.
2017-02-28 English
Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants
Share Issue/Capital Change Classification · 91% confidence The document is a corporate announcement detailing a share capital increase through the issuance of new shares upon exercise of employee warrants, including the number of shares at various exercise prices and the total proceeds. This is not a full financial report, earnings release, or AGM material, but specifically a notice of changes in the company’s share capital. Under our taxonomy, this falls under Share Issue/Capital Change (Code: SHA).
2017-02-28 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.